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Abstract
Background Irinotecan hydrochloride and S-1, an oral
ﬂuoropyrimidine, have shown antitumor activity against
advanced gastric cancer as single agents in phase I/II
studies. The combination of irinotecan and S-1 (IRI-S) is
also active against advanced gastric cancer. This study was
conducted to compare the efﬁcacy and safety of IRI-S
versus S-1 monotherapy in patients with advanced or
recurrent gastric cancer.
Methods Patients were randomly assigned to oral S-1
(80 mg/m
2 daily for 28 days every 6 weeks) or oral S-1
(80 mg/m
2 daily for 21 days every 5 weeks) plus irino-
tecan (80 mg/m
2 by intravenous infusion on days 1 and 15
every 5 weeks) (IRI-S). The primary endpoint was overall
survival. Secondary endpoints included the time to treat-
ment failure, 1- and 2-year survival rates, response rate,
and safety.
Results The median survival time with IRI-S versus S-1
monotherapy was 12.8 versus 10.5 months (P = 0.233),
time to treatment failure was 4.5 versus 3.6 months
(P = 0.157), and the 1-year survival rate was 52.0 versus
44.9%, respectively. The response rate was signiﬁcantly
higher for IRI-S than for S-1 monotherapy (41.5 vs. 26.9%,
P = 0.035). Neutropenia and diarrhea occurred more fre-
quently with IRI-S, but were manageable. Patients treated
with IRI-S received more courses of therapy at a relative
dose intensity similar to that of S-1 monotherapy.
Conclusions Although IRI-S achieved longer median
survival than S-1 monotherapy and was well tolerated, it
did not show signiﬁcant superiority in this study.
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Gastric cancer is the second leading cause of cancer-related
deaths after lung cancer in Japan, and it was responsible for
approximately 50,000 deaths in 2005 [1]. While surgery
and appropriate adjuvant chemotherapy have resulted in
superior stage-by-stage survival when compared with that
in other parts of the world [2], the prognosis of unresec-
table or recurrent gastric cancer remains dismal. The
development of more effective chemotherapeutic regimens
is therefore warranted.
In Western countries where a combination of 5-ﬂuoro-
uracil (5-FU) and cisplatin (CDDP) [3] has served as a
reference arm in several phase III studies [4–6], triplets
employing epirubicin [7] or docetaxel [5] in addition to this
combination are the current standards, with modiﬁcations
such as the replacement of CDDP with oxaliplatin and the
replacement of infusional 5-FU with oral agents such as
capecitabine [8]. Failure with the ﬁrst-line treatment usu-
ally denotes the termination of chemotherapy, and second-
line treatments are rarely considered outside of clinical
trials. In Japan, where a phase III study (JCOG9205) failed
to show superiority of a 5-FU/CDDP combination over
5-FU alone [9], the 5-FU monotherapy remained a standard
of care, and other cytotoxic agents were usually delivered
sequentially as second-line and third-line therapies rather
than concurrently as combination therapy. With this strat-
egy, the median survival time (MST) of patients with
advanced gastric cancer whose treatment started with in-
fusional 5-FU alone actually reached 10.8 months [9].
In the 1990s, S-1 (TS-1; Taiho Pharmaceutical, Tokyo,
Japan), an oral derivative of 5-FU, was developed for the
treatment of gastric cancer [10–12]. With an exceptionally
high response rate of 46% as a single agent, this drug
rapidly established itself as a community standard in Japan
and was used widely in clinical practice. Phase III trials
eventually proved the non-inferiority of S-1 when com-
pared with infusional 5-FU in the advanced/metastatic
setting [13], along with the superiority of S-1 monotherapy
over observation alone in the postoperative adjuvant setting
[14]. In addition, S-1 was found to be a unique cytotoxic
drug, in that Japanese patients tolerated higher doses than
Western patients, due to differences in the gene polymor-
phism of relevant enzymes [15]. Thus, the development of
novel chemotherapeutic regimens in Japan during the
2000s has inevitably centered around this drug.
The establishment of doublets to enhance response rates
and improve on survival was the next important step, and
several phase I/II studies were performed to explore com-
binations of S-1 with other cytotoxic drugs such as CDDP
[16], docetaxel [17], paclitaxel [18], and irinotecan (Yakult
Honsha, Tokyo, Japan; Daiichi Sankyo, Tokyo, Japan)
[19]. All these combinations were found to be promising,
with response rates of around 50% and relatively favorable
safety proﬁles. A series of phase III trials comparing these
doublets with S-1 monotherapy were subsequently planned
and conducted to seek optimal ﬁrst-line treatments. Of
these, a phase III trial to explore S-1/CDDP was the ﬁrst to
complete accrual, and a signiﬁcant improvement in MST of
this combination over S-1 monotherapy was proven [20].
The present study, entitled GC0301/TOP-002, represents
another of these attempts, exploring the efﬁcacy of a
combination of S-1 and irinotecan (IRI-S). The dose and
schedule for this combination had been established by a
phase I trial [21], and treatment at the recommended dose
has shown a response rate of 47.8% [95% conﬁdence
interval (CI) 27.4–68.2%] with an MST of 394 days in a
phase II study [19]. Given these earlier results and the
synergistic effect of irinotecan and 5-FU observed in pre-
clinical studies, the results of this present trial have been
eagerly awaited.
Patients and methods
Eligibility
The eligibility criteria were histologically and cytologically
conﬁrmed unresectable or recurrent gastric adenocarci-
noma; oral food intake possible; age between 20 and
75 years; no prior radiotherapy or chemotherapy; expected
survival for C12 weeks; Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2; and adequate
major organ function before chemotherapy (leukocyte
count of 4,000–12,000/mm
3, hemoglobin C 8.0 g/dl,
platelet count C 100,000/mm
3, total bilirubin B 1.5 mg/
dl, aspartate aminotransferase B 100 IU/l, alanine amino-
transferase B 100 IU/l, creatinine B 1.2 mg/dl). The main
exclusion criteria were massive ascites, active concomitant
malignancy, uncontrolled diabetes mellitus, and pregnancy
or breast-feeding. Written informed consent was obtained
from each patient. Institutional review board approval was
obtained at each participating institution. An independent
data monitoring committee evaluated safety throughout
this study. The study was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines. This trial was registered with the Japan Phar-
maceutical Information Center (JapicCTI-050083).
Treatment schedule
In the S-1 monotherapy group, patients received oral S-1
twice daily for 28 days every 6 weeks. In the IRI-S group,
S-1 (80 mg/m
2) was given orally for 21 days and irino-
tecan (80 mg/m
2) was infused intravenously on days 1 and
15 every 5 weeks. In both groups, the dose of S-1 was
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\1.25 m
2; 50 mg for 1.25–1.5 m
2, and 60 mg for C1.5 m
2.
Dose modiﬁcation criteria were deﬁned in the protocol.
Treatment was discontinued if there was documented dis-
ease progression, unacceptable toxicity, or withdrawal of
consent.
Assessment of response and toxicity
All patients who had at least one measurable lesion were
evaluated for tumor response according to the Response
Evaluation Criteria in Solid Tumors (RECIST) [22]. All
radiologic assessments were conﬁrmed by extramural
review. Toxicity was evaluated according to the National
Cancer Institute Common Toxicity Criteria (version 2.0).
Statistical analysis
Eligible patients were registered with the data center and
randomized by centralized dynamic allocation with strati-
ﬁcation for advanced/recurrent disease (with or without
adjuvant chemotherapy), performance status (0/1/2), and
institution. The full analysis set was deﬁned as all patients
who received treatment at least once and met all inclusion
criteria. The per-protocol set was deﬁned as all patients
who received treatment at least once and had no major
protocol violations.
The primary endpoint was overall survival, which was
compared between groups using the stratiﬁed log-rank test.
Secondary endpoints were the time to treatment failure
(TTF), the 1- and 2-year survival rates, the response rate,
and safety. Overall survival time was deﬁned as the
interval from the date of registration to the date of death
(patients who remained alive at the ﬁnal follow-up were
censored at that time). Survival curves were estimated by
the Kaplan–Meier method, and differences were analyzed
with the stratiﬁed log-rank test. Hazard ratios (HRs) for
various prognostic factors were calculated using a stratiﬁed
Cox proportional hazards model. TTF was deﬁned as the
time from the date of registration to the date of detection of
progressive disease, death, or treatment discontinuation.
In addition, subset analyses were conducted, using the
Cox proportional hazards model, to identify factors that
inﬂuenced overall survival in each group. As well as the
predetermined variables such as gender, age, performance
status, and disease status (whether the disease was unre-
sectable or recurrent), subset analyses were conducted for 6
additionalvariables;thepresenceorabsenceofameasurable
lesion by the RECIST, hepatic metastasis, peritoneal
metastasis, existent of primary focus, metastasis the number
of metastatic foci, and tumor histology. All analyses were
performed using SAS system version 8.2 (SAS Institute,
Cary, NC, USA).
This study was designed to detect a 40% improvement
in MST at a two-tailed signiﬁcance level of P B 0.05 with
80% power. The MST for S-1 monotherapy was assumed
to be 8.5 months, based on the results of previous phase I/II
studies [12, 23]. A total of 142 patients per group were
required according to calculations made with nQuery
Advisor version 4.0 (Statistical Solutions, Boston, MA,
USA), and the sample size was set as 300 (150 patients per
group).
Weinitiallyplanned tocontinue follow-up forC1.5 years
after the registration of all patients, with a cut-off date of
April 2007. However, an unexpectedly high survival rate
of 22% (68 of 315 patients) at the cut-off date prompted
the Coordinating Committee, the medical expert, and
thebiostatisticiantoadvisethesponsortocontinuefollow-up
for a further year before performing the ﬁnal analysis.
Thus, the MST was also calculated using 2.5-year follow-
up data.
Results
Patient characteristics
Between June 2004 and November 2005, a total of 326
patients (S-1 monotherapy, n = 162; IRI-S, n = 164) were
enrolled from 54 institutions and randomized (Fig. 1).
Seven patients were subsequently found to be ineligible or
withdrew before receiving any treatment. Another 4
patients were found to be ineligible after starting treatment
and were not included in the analysis. Therefore, 315
patients (S-1 monotherapy, n = 160; IRI-S, n = 155) were
evaluable and were included in the full analysis set to
assess overall survival and TTF. In addition, 187 patients
were evaluable for tumor response. Baseline patient char-
acteristics are shown in Table 1.
Treatments given
The median number of treatment courses was three (range
1–19) for S-1 monotherapy whose duration was 6 weeks,
and four (range 1–25) for IRI-S whose duration was
5 weeks. The main reasons for treatment discontinuation
were disease progression [S-1 monotherapy vs. IRI-S,
116/160 (72.5%) vs. 89/155 (57.4%)], adverse events [12/
160 (7.5%) vs. 23/155 (14.8%)], attending physician’s
decision [18/160 (11.3%) vs. 18/155 (11.6%)], and consent
withdrawal [11/160 (6.9%) vs. 17/155 (11.0%)]. The
median TTF was 3.6 months (95% CI 2.9–4.1) and
4.5 months (95% CI 3.7–5.3), respectively (P = 0.157).
The relative dose intensity was 88.9% for S-1 mono-
therapy, versus 90.0% for S-1 and 86.2% for irinotecan
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123among those treated with IRI-S. Most patients in both
groups received the scheduled dose of chemotherapy.
Second-line chemotherapy was administered to 240
patients (76%; S-1 monotherapy, n = 112; IRI-S,
n = 128) (Table 2). The most common second-line ther-
apy in both groups was a taxane alone (S-1 monotherapy,
26.9%; IRI-S, 40.6%). Among patients initially treated
with S-1, 13 received crossover treatment with IRI-S, while
31 patients originally treated with IRI-S received second-
line S-1 monotherapy.
Response and survival
The overall response rate was determined in 187 patients
evaluable by the RECIST, and was signiﬁcantly higher
with IRI-S than with S-1 monotherapy (39/94, 41.5% vs.
25/93, 26.9%; P = 0.035) (Table 3).
The MST at the predetermined cut-off date was
12.8 months with IRI-S compared with 10.5 months with
S-1 monotherapy (HR 0.856, P = 0.233) (Fig. 2), but the
difference was not statistically signiﬁcant. The 1-year
survival rates were 44.9% [95% CI 37.2–52.6%] with S-1
monotherapy and 52.0% (95% CI 44.1–59.9%) with IRI-S,
while the 2-year survival rates were 19.5% (95% CI
12.6–26.4%) and 18.0% (95% CI 11.2–24.8%),
respectively.
MST was additionally calculated as an exploratory
analysis after 2.5 years of follow-up, but the result was
identical to the initial analysis at 12.8 months for IRI-S and
at 10.5 months for S-1 monotherapy (HR 0.927; log-rank
test P = 0.536). Again, the difference was not statistically
signiﬁcant.
Prognostic factors of all patients and factors
that favored treatment with IRI-S
Baseline risk factors with a signiﬁcant inﬂuence on the
overall survival of all patients accrued (P\0.05) were
performance status (HR 1.348, 95% CI 1.079–1.686, Wald
test P = 0.009), tumor histology (HR 1.720, 95% CI
Screened and randomized to treatment (n=326)
IRI-S (n=164)
Excluded (n=6) 
S-1 (n=162)
Excluded (n=1) 
Found ineligible before
1st treatment (n=2)
Consent withdrawn (n=1)
Clinical /laboratory
abnormalities (n=3)
Clinical/laboratory
abnormalities (n=1)
Treated with S-1 (n=161)
Ineligible (n=1)
Tumor other than
adenocarcinoma(n=1)
Treated with IRI-S (n=158)
Ineligible (n=3)
Consent withdrawn and
no measrable and no
assessable metastatic 
disease (n=1)
Postoperative adjuvant
chemotherapy (n=1)
No measurable and no
assessablemetastatic
disease (n=1)
Primary analysis endpoint
Overall survival
Primary analysis endpoint
Overall survival
FAS (n=160)
Secondary analyses
TTF: FAS (n=160)
Tumor response: FAS
(n=93)
Safety: PPS (n=160)
FAS (n=155)
Secondary analyses
TTF: FAS (n=155)
Tumor response: FAS
(n=94)
Safety: PPS (n=155)
Fig. 1 Patient disposition. FAS Full analysis set, IRI-S S-1 plus
irinotecan, PPS per-protocol set, TTF time to treatment failure
Table 1 Baseline characteristics and prior therapy
Characteristic Treatment
S-1 IRI-S Total
n % n % n %
Patients randomized 162 164 326
Patients receiving at least
one dose of study medication
(full analysis set)
160 155 315
Sex
Male 127 79 110 71 237 75
Female 33 21 45 29 78 25
Age (years)
Median 63 63 63
Range 27–75 33–75 27–75
ECOG performance status
0 109 68 102 66 211 67
1 4 62 9 4 83 1 9 43 0
2 5 35 31 0 3
Tumor histology
Intestinal 71 44 61 39 132 42
Diffuse 88 55 93 60 181 57
Other 1 1 1 1 2 1
Resection of primary tumor
? 93 58 93 60 186 59
- 67 42 62 40 129 41
Advanced 133 83 129 83 262 83
Recurrent
Adjuvant chemotherapy (?) 5 35 31 0 3
Adjuvant chemotherapy (-)2 21 4 2 11 4 4 31 4
IRI-S S-1 plus irinotecan, ECOG Eastern Cooperative Oncology
Group
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1231.161–2.548, P = 0.007), target lesion (HR 1.525, 95% CI
1.164–1.999, P = 0.002), and surgery for the primary
tumor (HR 0.698, 95% CI 0.538–0.906, P = 0.007).
Stratiﬁed analysis according to baseline patient charac-
teristics (Fig. 3) showed that IRI-S was signiﬁcantly more
effective than S-1 monotherapy for patients with diffuse-
type histology (HR 0.632, 95% CI 0.454–0.880) and for
those with an ECOG performance status of 1 or 2 (HR
0.614, 95% CI 0.401–0.940). No differences were observed
for the other factors assessed.
Safety
Adverse events that occurred in each group are listed in
Table 4. The incidence of major hematological toxicities
was higher with IRI-S than with S-1 monotherapy. Grade 3
or 4 neutropenia was observed in 10.6% of patients treated
with S-1 monotherapy versus 27.1% of patients treated
with IRI-S, while the corresponding incidences of infec-
tion/febrile neutropenia were 3.8 versus 1.9%. The most
common grade 3 or 4 non-hematological toxicities were
diarrhea (S-1 monotherapy vs. IRI-S, 5.6 vs. 16.1%),
anorexia (18.8 vs. 17.4%), nausea (5.6 vs. 7.1%), and
vomiting (1.9 vs. 3.2%). Hand-foot skin reaction, a char-
acteristic adverse event associated with some oral ﬂuoro-
pyrimidines, was conﬁned to grade 2 or less and was
observed in only 4.4 and 5.2% of patients treated with S-1
monotherapy and IRI-S, respectively. There were no
treatment-related deaths among patients treated with S-1
monotherapy, whereas two patients in the IRI-S died of
potentially treatment-related conditions (severe bone mar-
row dysfunction, multiple organ failure that was probably
associated with multiple duodenal ulcers).
Discussion
This study was conducted to determine whether IRI-S
could prolong MST compared with S-1 monotherapy.
Basic studies have indicated that irinotecan has a mul-
tifactorial synergistic effect with the anti-tumor activity
Table 2 Second-line chemotherapy
Regimen S-1 (n = 160) IRI-S (n = 155)
n % n %
IRI-S 13 8.1 – –
Irinotecan-based regimen
a 27 16.9 4 2.6
S-1 alone – – 31 20.0
S-1-based regimen
b 9 5.6 11 7.1
Taxane alone 43 26.9 63 40.6
Others 20 12.5 19 12.3
None 48 30.0 27 17.4
IRI-S S-1 plus irinotecan
a Irinotecan/cisplatin, irinotecan/taxane
b S-1/cisplatin, S-1/taxane
Table 3 Response to treatment
S-1 (n = 93) IRI-S (n = 94)
n % n %
Complete response 0 0 0 0
Partial response 25 27 39 41
Stable disease 35 38 40 43
Progressive disease 30 32 12 13
Not assessable 3 3 3 3
Overall response rate 26.9 41.5*
95% CI 18.2–37.1 31.4–52.1
CI conﬁdence interval
* P = 0.035 (v
2 test)
a
100
90
60
70
80
S-1 :
MST = 10.5 months (95% CI 9.4–13.0)
IRI-S:
MST = 12.8 months (95% CI 10.7–15.1)
20
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40
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S
u
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a
l
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(
%
)
6.0 12.0 18.0 0
Months
Patients at risk
10
0
160 120 71 40
155 127 80 42
b
S-1 :
Median TTF = 3.6 months (95% CI 2.9–4.1) 
IRI-S:
100
90
Median TTF = 4.5 monts (95%CI37–5.3) 
50
60
70
80
T
T
F
 
(
%
)
10
20
30
40
0
S-1
IRI-S
S-1
IRI-S
24.0 30.0 36.0
6.0 12.0 18.0 0
Months
Patients at risk
24.0 30.0 36.0
Arm A
ArmB
14 2 0
3 0 12 3 0
Arm A
Arm B
160 41 14 5
155 49 14 5
20 0
21 0
Fig. 2 Kaplan–Meier estimates of overall survival (a) and time to
treatment failure (b) for 315 evaluable patients treated with S-1
monotherapy or S-1 plus irinotecan (IRI-S). MST Median survival
time, TTF time to treatment failure, CI conﬁdence interval
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123of 5-FU [24, 25]. In addition, several trials exploring
combinations of S-1 and irinotecan have reported
promising response rates [19, 23, 26, 27]; the dose and
schedule in the present study was selected based on the
lower incidence of grade 3 neutropenia and gastrointes-
tinal toxicity evidenced from phase II studies among
these trials.
Although the combination therapy in the present study
achieved a signiﬁcantly higher response rate, the initial
expectation that the addition of irinotecan would improve
the MST by 40% was not met. Thus, the combination of
S-1 and CDDP remains the ﬁrst-line chemotherapy that can
be recommended for Japanese patients, while patients who
are frail or those who wish to refrain from the short stay in
the hospital required for hydration could turn to S-1
monotherapy. Another standard treatment could be avail-
able pending the results of a phase III trial comparing S-1
with an S-1/docetaxel combination [17]. A combination of
CDDP with 5-FU or its derivative capecitabine has been
used as a platform for molecularly targeting agents in
recent international trials [28]; however, the place of
platinum agents in the ﬁrst-line treatment of gastric cancer
would seem indispensible at present.
Irinotecan has often been delivered in combination with
CDDP for gastric cancer in the West [29]. This combina-
tion was also explored in Japan in a phase II trial [30] and
subsequently in a phase III trial [13], but failed to show
statistically signiﬁcant superiority over infusional 5-FU
alone. Irinotecan was more recently found to be similarly
effective to CDDP when delivered with 5-FU [31], with
beneﬁt in terms of a more favorable toxicity proﬁle. The
combination then went on to be compared with a 5-FU/
CDDP combination [4], but, again, failed to show a sur-
vival advantage. With similar results obtained from the
present study, irinotecan-based chemotherapy would no
longer be expected to surpass 5-FU or its derivatives with
or without CDDP in the ﬁrst-line setting.
Our stratiﬁed analysis revealed that IRI-S had a signif-
icant effect on overall survival in patients with diffuse-type
histology and an ECOG performance status of 1 or 2
(Fig. 3). IRI-S was more effective in symptomatic patients.
This ﬁnding may be related to its higher response rate,
Patients,n
Sex
Male 237 0 876 [0 656 1 170]
Hazard ratio (95%CI)
Male 237 0.876 [0.656 - 1.170]
8 7 Female 0.939 [0.566 - 1.557]
Age, years
8 7 1 < 65 0.850 [0.613 - 1.177]
7 3 1 >=65 0.936 [0.634 - 1.381]
Histology
Intestinal 132 1.310 [0.890 - 1.928]
1 8 1 Diffuse 0.632 [0.454 - 0.880]
ECOG Performance status
1 1 2 0 1.052 [0.772 - 1.434]
4 0 1 2 or 1 0.614 [0.401 - 0.940]
Disease status
Unresectable 262 0.822 [0.624 - 1.082]
Recurrent(+ Adjuvant) 10 0.319 [0.074 - 1.377] 0 03 9 [ 00 3 ]
Recurrent(- Adjuvant) 43 1.744 [0.881 - 3.453]
RECIST assessment
7 8 1 Done 0.890 [0.649 - 1.219]
8 2 1 Not done 0.864 [0.572 - 1.305]
Liver
5 0 2 ) - ( 0.943 [0.687 - 1.295]
(+) 110 0 866 [0 576 1 301] (+) 110 0.866 [0.576 - 1.301]
Peritoneum
0 1 2 ) - ( 0.830 [0.610 - 1.130]
5 0 1 ) + ( 1.018 [0.662 - 1.565]
Primary focus
9 1 1 ) - ( 1.066 [0.695 - 1.637]
6 9 1 ) + ( 0.775 [0.570 - 1.054]
No. of foci
1 0 -
3 2 1 1 1.019 [0.672 - 1.545]
1 9 1 2 = > 0.803 [0.588 - 1.098]
5 1 3 Total 0.893 [0.696 - 1.146]
4.0 2.0 1.0 0.5 0.25
IRI-S Better S-1 Better
Fig. 3 Subset analysis of overall survival stratiﬁed by baseline patient characteristics. CI Conﬁdence interval, ECOG Eastern Cooperative
Oncology Group, RECIST Response Evaluation Criteria in Solid Tumors
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123resulting from tumor shrinkage, with subsequent attenua-
tion of clinical symptoms, possibly leading to enhanced
survival time. The effect of IRI-S in cancer with diffuse-
type histology was in line with the ﬁnding of the subset
analysis of another phase III study that an irinotecan/CDDP
combination improved the survival of patients with undif-
ferentiated gastric cancer [13]. However, these data are
contradictory to data from a phase II study of the combi-
nation of S-1 and irinotecan [19], where a higher response
rate was observed for intestinal-type histology. It would not
seem feasible at this time, therefore, to attempt to identify
patients who may beneﬁt from the IRI-S, using clinico-
pathologic factors that are easily accessible.
As mentioned previously, cytotoxic drugs tend to be
used sequentially as second-line and third-line therapies in
some countries, including Japan. Recently, Thuss-Patience
et al. [32] reported on second-line treatment for metastatic
gastric cancer, and stated that irinotecan monotherapy
signiﬁcantly extended survival compared with best sup-
portive care. A retrospective study exploring a combination
of irinotecan and CDDP for patients who failed ﬁrst-line
therapy with S-1 has shown a promising response rate of
28.6% and a MST of 9.4 months from the ﬁrst day of the
second-line treatment [33]. Another retrospective study,
also in the second-line setting, has shown promising MSTs,
ranging from 9.5 to 10.1 months [34]. These studies sug-
gest a role for irinotecan after the failure of a 5-FU-based
ﬁrst-line treatment, provided that the patients retain sufﬁ-
cient performance status to tolerate this drug. Because
deﬁnite evidence remains unavailable, further prospective
studies in the second-line and third-line settings are war-
ranted to conﬁrm the place of irinotecan in the treatment of
gastric cancer. IRI-S uses up one of promising drug com-
bination for the second line treatment without sufﬁcient
prolongation of TTF when compared with S-1 mono-
therapy. It could partially explain why the combination
failed to attain signiﬁcant gain in MST in the present study.
IRI-S was generally well tolerated in the present study.
The dose intensity of S-1 in patients treated with IRI-S was
equivalent to that in patients receiving S-1 monotherapy,
demonstrating the good tolerability of the IRI-S. The most
common grade 3 or 4 adverse events associated with this
regimen included neutropenia (27.1%) and diarrhea
(16.1%), both of these being more frequent than in patients
receiving S-1 monotherapy. IRI-S appears to be better
tolerated than either the S-1/CDDP or irinotecan/CDDP
regimens explored in other phase III studies [13, 20]. Grade
3 or 4 neutropenia was less common with IRI-S than with
the S-1/CDDP and irinotecan/CDDP regimens (27 vs. 40%
and 65%, respectively), as was anorexia (17 vs. 30% and
33%) and nausea (7 vs. 12% and 21%). Only diarrhea was
more common with IRI-S than with the S-1/CDDP and
irinotecan/CDDP regimens (16 vs. 4% and 9%, respec-
tively) [13, 20]. However, it is of note that, in the present
study, two patients who received IRI-S died of potentially
treatment-related conditions. The evaluation of uridine
50-diphospho-glucuronosyl-transferase gene polymor-
phism, which had notbeen approved at the time the trial was
conducted, could now identify a small number of patients
who may suffer from overt adverse reactions to IRI-S [35].
Although manageable in most cases, the IRI-S was
found to be more toxic than S-1 monotherapy. To con-
clude, the improvement in the response rate observed with
the IRI-S did not translate into the predicted prolongation
of MST.
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Anorexia 104 65.0 30 18.8 125 80.6 27 17.4
Diarrhea 63 39.4 9 5.6 103 66.5 25 16.1
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